TeloCure
Gene Therapy for Hoyeraal-hreidarsson Syndrome
Health Tech & Life Sciences
Non Active, Oct 2019 ceased to operate
Company Overview
Snapshot
Founded in July 2018 by Noam Diamant, TeloCure operates with 1-10 employees. The company ceased operations in October 2019.
Business overview
TeloCure is a Health Tech & Life Sciences company focused on developing gene therapy for Hoyeraal-Hreidarsson syndrome, an ultra-rare disease characterized by excessively short telomeres. This condition is considered a severe form of dyskeratosis congenita. The company operates within the Pharmaceuticals sector, targeting the Healthcare & Life Sciences industry with a B2B business model.
Company Intelligence Q&A
- What is TeloCure's primary focus?
- TeloCure aims to develop a gene therapy specifically for Hoyeraal-Hreidarsson syndrome, an ultra-rare disease linked to excessively short telomeres.
- When was TeloCure founded?
- TeloCure was founded in July 2018.
- Who founded TeloCure?
- TeloCure was founded by Noam Diamant, who also serves as the Co-founder & CEO.
- What is the operational status of TeloCure?
- TeloCure ceased operations in October 2019.
- In which sector does TeloCure primarily operate?
- TeloCure operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.